Dubai: In a major step towards transforming the region as a hub for pharmaceutical production and export, VPS Healthcare’s medicine manufacturing arm, LIFEPharma, will be exploring new avenues entering into the European and American markets.
In a first of its kind, LIFEPharma, the region’s sole US FDA-certified pharmaceutical unit, will become the first to enter the US market exporting conventional medicines. Initially, the company will be exporting around 25,000 bottles of Acetazolamide collaborating with Eywa, a leading pharmaceutical production company in the US, announced company officials here at the Arab Health Summit.
The first batch of the medicines, locally produced at LIFEPharma’s production plant in Jebel Ali, will be exported in this week. Subsequently, the unit will be manufacturing and exporting more products, particularly in the cardiovascular and diuretic therapy areas.
Apart from this, on the backdrop of Arab Health, LIFEPharma struck a major deal with leading European multinational company, XO Laboratory, based in France. As per the MoU signed between the entities, LIFEPharma will be producing a significant number of XO’s products locally in the UAE and import unique medicines such as Alendronic acid solution, Mynocycline, Alginic acide sachets and Ketoprofen/Omeprazole from France to the UAE market. The MoU was signed by LIFEPharma CEO Dr. Madgy Fahmy and XO Laboratory Director General Karine Pinon in the presence of VPS Healthcare Chairman & Managing Director Dr. Shamsheer Vayalil.
In 2019, LifePharma had signed a significant deal with Canadian giant Apotex, the largest producer of generic medicines in North America, to produce generic medicines to be exported to North American markets. The pharmaceutical manufacturer has started producing a billion tablets annually to be exported to North America.
Dr. Shamsheer said that LifePharma has become a crucial player in the Middle East and has contributed immensely to transform the region in becoming a hub for pharmaceutical production. “The year 2019 has seen one of our products being exported to the North American markets. It was a great achievement for us. In 2020, we will be exporting six more products to North America. We are the first in the region to do this. This year, we expect to get into more markets and improve our global footing.”
Speaking about the tie-up, Pinone said XO Laboratory was honored and privileged to partner with LIFEPharma. “We believe that our joint venture will make a difference for the patients in the future. We are confident our agreement will pave way towards a higher level of collaboration between France and the UAE.”
© Press Release 2020Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
